The study, titled “The protective effect of sodium-glucose cotransporter-2 inhibitor on left ventricular global longitudinal strain in patients with type 2 diabetes mellitus according to disease duration,” investigates the impact of SGLT2 inhibitors on heart function in type 2 diabetes patients.
The study investigated the effects of canagliflozin (CANA), a sodium-glucose transporter-2 inhibitor (SGLT2i), on bone health using genetically heterogeneous UM-HET3 mice. CANA is typically used to lower blood glucose levels independently of insulin but also induces various metabolic changes, including weight loss and impaired bone integrity. The research aimed to understand how CANA affects bone metabolism, given that SGLT2 is not expressed in osteoblasts or osteocytes, which are crucial for bone remodeling.
This research examines the effect of different glucose-lowering drugs on the risk of exacerbations of chronic obstructive pulmonary disease (COPD) in patients with type 2 diabetes (T2D) and active COPD. With the assistance of three large U.S.
The FDA has issued a clinical hold on Amgen’s phase I trial of the experimental weight-loss drug AMG 513. In other news, Children’s Hospital Los Angeles has suspended the initiation of puberty blockers in transgender patients younger than 19 after an executive order from former President Trump. Defense Secretary Pete Hegseth has also directed the military to suspend the integration of new transgender recruits and to suspend medical treatment for troops with gender dysphoria.
The research assesses the safety and efficacy of non-vitamin K antagonist oral anticoagulants (NOACs) versus placebo or antiplatelet therapy following acute myocardial infarction (AMI) in patients with no indication for anticoagulation. A systematic review and network meta-analysis of six randomized controlled trials (RCTs) including 33,039 patients compared rivaroxaban, apixaban, and dabigatran. Rivaroxaban lowered all-cause mortality (risk ratio [RR] 0.82) and likely cardiovascular mortality (RR 0.83), and dabigatran had a likely reduction in all-cause mortality but with low-certainty evidence. Apixaban did not affect mortality outcomes.
